Truist Financial Cuts Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $85.00
Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price objective trimmed by Truist Financial from $175.00 to $85.00 in a research note released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other research analysts have also issued reports on PRAX. Needham & Company LLC cut their target […]
